Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Net Income (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Net Income for 9 consecutive years, with $144.4 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 5.4% to $144.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Dec 2025, up 554.34% year-over-year, with the annual reading at $93000.0 for FY2025, 103.94% up from the prior year.
  • Net Income hit $144.4 million in Q4 2025 for Sutro Biopharma, up from -$56.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $152.7 million in Q4 2024 to a low of -$65.3 million in Q1 2025.
  • Historically, Net Income has averaged -$15.6 million across 5 years, with a median of -$36.4 million in 2021.
  • Biggest five-year swings in Net Income: tumbled 322.82% in 2022 and later surged 391.53% in 2024.
  • Year by year, Net Income stood at -$38.1 million in 2021, then rose by 9.26% to -$34.6 million in 2022, then surged by 189.78% to $31.1 million in 2023, then soared by 391.53% to $152.7 million in 2024, then decreased by 5.4% to $144.4 million in 2025.
  • Business Quant data shows Net Income for STRO at $144.4 million in Q4 2025, -$56.9 million in Q3 2025, and -$11.5 million in Q2 2025.